Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Molecular Pharmaceutics

• Publication date

  2011-12-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp200291xPMID 21905667PMCID PMC3304100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.

  2009cited by this paper
• Prodrugs: design and clinical applications

  2008cited by this paper
• Molecular Basis of Prodrug Activation by Human Valacyclovirase, an α-Amino Acid Ester Hydrolase*

  2008cited by this paper
• Vaccines and Antiviral Drugs in Pandemic Preparedness

  2006cited by this paper
• The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.

  2006cited by this paper
• Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

  2006cited by this paper
• Floxuridine Amino Acid Ester Prodrugs: Enhancing Caco-2 Permeability and Resistance to Glycosidic Bond Metabolism

  2005cited by this paper
• Avian flu: Isolation of drug-resistant H5N1 virus

  2005cited by this paper
• Neuraminidase inhibitors for influenza.

  2005cited by this paper
• Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.

  2005cited by this paper
• Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs

  2005cited by this paper
• Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds

  2004cited by this paper
• A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

  2004cited by this paper
• Lessons learned from marketed and investigational prodrugs.

  2004cited by this paper
• Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network

  2003cited by this paper
• Improved Synthesis of Amino Acid and Dipeptide Chloromethyl Esters Using Bromochloromethane

  2003cited by this paper
• Amino Acid Ester Prodrugs of Floxuridine: Synthesis and Effects of Structure, Stereochemistry, and Site of Esterification on the Rate of Hydrolysis

  2003cited by this paper
• Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

  2003cited by this paper
• Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.

  2003cited by this paper
• Current perspectives on established and putative mammalian oligopeptide transporters.

  2003cited by this paper
• Mammalian peptide transporters as targets for drug delivery.

  2002cited by this paper
• Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases.

  2001cited by this paper
• Targeted prodrug design to optimize drug delivery

  2000cited by this paper
• Incidence of Amantadine‐Resistant Influenza A Viruses in Sentinel Surveillance Sites and Nursing Homes in Niigata, Japan

  2000cited by this paper
• Drug transport and targeting. Intestinal transport.

  1999cited by this paper
• Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers

  1999cited by this paper
• Overexpression of Human Intestinal Oligopeptide Transporter in Mammalian Cells via Adenoviral Transduction

  1998cited by this paper
• 5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter

  1998cited by this paper
• The synthesis and enzymatic incorporation of sialic acid derivatives for use as tools to study the structure, activity, and inhibition of glycoproteins and other glycoconjugates.

  1998cited by this paper
• Cellular Uptake Mechanism of Amino Acid Ester Prodrugs in Caco-2/hPEPT1 Cells Overexpressing a Human Peptide Transporter

  1998cited by this paper
• Improved oral drug delivery: solubility limitations overcome by the use of prodrugs

  1996cited by this paper
• Comparison Between Permeability Coefficients in Rat and Human Jejunum

  1996cited by this paper
• Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-Ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-D-erythro-L-gluco-nononic acid

  1995cited by this paper
• Tranexamic acid derivatives with enhanced absorption.

  1986cited by this paper
• Rationale for design of biologically reversible drug derivatives: prodrugs.

  1975cited by this paper

• Zanamivir-Amantadine Conjugate: A Dual-Action Agent with Broad-Spectrum Synergistic Antiviral Efficacy.

  2026cites this paper
• SLC15 family of peptide transporters in GtoPdb v.2025.3

  2025cites this paper
• A Novel Prodrug Strategy Based on Reversibly Degradable Guanidine Imides for High Oral Bioavailability and Prolonged Pharmacokinetics of Broad-Spectrum Anti-influenza Agents

  2024cites this paper
• Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design.

  2024cites this paper
• Transporter-Mediated Drug Delivery

  2023cites this paper
• SLC15 family of peptide transporters in GtoPdb v.2023.1

  2023cites this paper
• Towards Effective Antiviral Oral Therapy: Development of a Novel Self-Double Emulsifying Drug Delivery System for Improved Zanamivir Intestinal Permeability

  2023cites this paper
• Enabling Oral Delivery of Antiviral Drugs: Double Emulsion Carriers to Improve the Intestinal Absorption of Zanamivir.

  2022cites this paper
• Using drug chemical structures in the education of pharmacology and clinical therapeutics key concepts

  2022cites this paper
• Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

  2021cites this paper
• Peptide Transporters

  2021cites this paper
• Oral drug delivery for immunoengineering

  2021cites this paper
• Computational Simulations to Guide Enzyme-Mediated Prodrug Activation

  2020cites this paper
• Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.

  2020cites this paper
• Recent advances in understanding prodrug transport through the SLC15 family of proton-coupled transporters

  2020cites this paper
• Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems.

  2020cites this paper
• Phototriggered Release of a Transmembrane Chloride Carrier from an o-Nitrobenzyl-Linked Procarrier.

  2019cites this paper
• Amino Acid Conjugation: An Approach to Enhance Aqueous Solubility and Permeability of Poorly Water Soluble Drug Ritonavir

  2019cites this paper
• SYNTHESIS AND EVALUATION OF AMINO ACID ESTER CONJUGATES OF HIV PROTEASE INHIBITOR

  2019cites this paper
• Development of effective anti-influenza drugs: congeners and conjugates – a review

  2019cites this paper
• The enhancing effect of N-acetylcysteine modified hyaluronic acid-octadecylamine micelles on the oral absorption of paclitaxel.

  2019cites this paper
• Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs.

  2019cites this paper
• Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.

  2018cites this paper
• Recent advances in improving oral drug bioavailability by cocrystals

  2018cites this paper
• Structural basis for prodrug recognition by the SLC15 family of proton coupled peptide transporters

  2018cites this paper
• Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

  2017cites this paper
• Prodrug approach: An overview of recent cases.

  2017cites this paper
• Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.

  2017cites this paper
• Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years

  2017cites this paper
• Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model

  2016cites this paper
• Development of Influenza Virus Sialidase Inhibitors

  2016cites this paper
• Structure-based model profiles affinity constant of drugs with hPEPT1 for rapid virtual screening of hPEPT1’s substrate

  2016cites this paper
• A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability.

  2016cites this paper
• Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue.

  2016cites this paper
• Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility–Permeability Interplay

  2016cites this paper
• In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities.

  2015cites this paper
• Getting across the cell membrane: an overview for small molecules, peptides, and proteins.

  2015cites this paper
• Zanamivir oral delivery: possibilities revisited.

  2015cites this paper
• Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model.

  2015cites this paper
• Gordon L. Amidon: Very Sustained Drug Absorption.

  2015cites this paper
• Interaction of Drug or Food with Drug Transporters in Intestine and Liver.

  2015cites this paper
• Prodrug strategies for brain delivery

  2015cites this paper
• Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.

  2015cites this paper
• From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?

  2014cites this paper
• Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Phosphonate Congeners of Oseltamivir and Zanamivir as Effective Anti‐influenza Drugs: Design, Synthesis and Biological Activity

  2014cites this paper
• Modern Prodrug Design for Targeted Oral Drug Delivery

  2014cites this paper
• Ligand-mediated active targeting for enhanced oral absorption.

  2014cites this paper
• Significance of Peptide Transporter 1 in the Intestinal Permeability of Valacyclovir in Wild-Type and PepT1 Knockout Mice

  2013cites this paper
• A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine.

  2013cites this paper
• Medicinal chemistry of amine prodrugs

  2013cites this paper
• Current status of rational design of prodrugs targeting the intestinal di/tri-peptide transporter hPEPT1 (SLC15A1)

  2013influential citation
• Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment

  2013cites this paper
• Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

  2013cites this paper
• Significance of Peptide Transporter 1 in the Intestinal Permeability of Valacyclovir in Wild-Type and PepT1 Knockout Mice

  2013cites this paper
• Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats

  2013cites this paper
• Significance of Peptide Transporter 1 in the Intestinal Permeability of Valacyclovir in Wild-Type and PepT1 Knockout Mice

  2013cites this paper
• Drug transport via the intestinal peptide transporter PepT1.

  2013cites this paper
• Human viral diseases: what is next for antiviral drug discovery?

  2012cites this paper
• Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach

  2012cites this paper
• Pharmacogenomics Dictate Pharmacokinetics: Polymorphisms in Drug-Metabolizing Enzymes and Drug-Transporters

  2012cites this paper
• Human viral diseases: what is next for antiviral drug discovery?

  2012cites this paper
• 11. Enabling Formulations

  2012cites this paper
• Role of peptide transporter PEPT1 in the intestinal absorption and pharmacokinetics of the amino acid ester prodrug valacyclover

  2012cites this paper
• Development of oseltamivir phosphonate congeners as anti-influenza agents.

  2012cites this paper
• 消化管トランスポ－タ－による医薬品の吸収促進

  2012cites this paper